OncoAlert and ecancer ASCO roundup - Day 1
OncoAlert and ecancer ASCO roundup - Day 1
Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC
NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC
ASCO 2021: Latest on PARPi and other treatments for mCRPC
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma
Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC
KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma
Rare inherited pathogenic germline variants observed in sporadic paediatric neuroblastoma cases
PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer
MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours
Mechanisms of acquired resistance to KRAS G12C inhibition in cancer